UNSPSC 51431607: Pargyline

This classification denotes a monoamine oxidase inhibitor and antihypertensive agent with the molecular formula C11H13N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9MV14S8G3E, chemically known as 2-propynylamine, n-benzyl-n-methyl-, hydrochloride but generally known as pargyline, which bears US NIH Compound Identifier 4688. European Medicines Agency schedules Pargyline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09626MIG.

UNSPSC 51431607 Pargyline is a Commodity code that in practice encompasses state and local procurement of emergency medical and pharmaceutical products — not pargyline specifically, but rather advanced life support medications, generic pharmaceuticals, and over-the-counter products distributed through authorized channels to fire rescue services, health and human services agencies, and multistate cooperative purchasing alliances. State and local governments procure these materials primarily through sealed competitive bidding (IFB) and request-for-proposal (RFP) vehicles, with purchasing departments at city and county levels managing direct supply contracts, while state health agencies and cooperative purchasing organizations manage broader platform agreements serving multiple jurisdictions and subordinate facilities. The City of Tampa's Purchasing Department and the Minnesota Department of Administration's Office of State Procurement stand out as active issuers under this code's practical scope; the Texas Health and Human Services Commission has also signaled forward procurement activity through exploratory request-for-information mechanisms.

Recent activity concentrates in Florida, Minnesota, and Texas. The City of Tampa issued IFB 26P00188 on April 24, 2026, for advanced life support medications (labetalol, epinephrine, adenosine, diltiazem) to supply Tampa Fire Rescue in Hillsborough County, with bids due April 8, 2026, an estimated contract value of $40,000.00, and a Small Local Business Enterprise set-aside with a 5 percent bid discount; the Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson to participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026, and contract effectiveness July 1, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling potential future formal procurement.